Active Biotech publishes prospectus and certain new financial information included in the prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW
The prospectus relating to Active Biotech AB’s (publ) rights issue has now been published and is available on the company’s website, www.activebiotech.com and on Mangold’s website, www.mangold.se. The prospectus can also be ordered from Active Biotech by telephone +46 (0)46 19 20 00.
New financial information included in the prospectus
The prospectus contains certain financial information regarding Active Biotech’s capital structure and net indebtedness as of 31 October 2020 that has not previously been published. The new financial information is presented in the tables below. The information has not been reviewed by the Company’s auditor.
Capitalization
| MSEK | 31 October 2020 |
| Current debt | |
| Guaranteed | – |
| Secured | – |
| Unguaranteed/unsecured | 1.3 |
| Total current debt | 1.3 |
| Non-current debt | |
| Guaranteed | – |
| Secured | – |
| Unguaranteed/unsecured | 0.9 |
| Total non-current debt (excluding the current debt as part of the non-current debt) | 0.9 |
| Shareholders’ equity | |
| Share capital | 0.8 |
| Legal reserve | – |
| Other reserves | 22.3 |
| Total equity | 23.1 |
Net indebtedness
| MSEK | 31 October 2020 |
| (A) Cash | – |
| (B) Cash equivalents | 28.1 |
| (C) Trading securities | – |
| (D) Liquidity (A)+(B)+(C) | 28.1 |
| (E) Current financial receivables | – |
| (F) Current bank debt | – |
| (G) Current portion of non-current debt | 1.3 |
| (H) Other current financial debt | – |
| (I) Other current financial debt (F)+(G)+(H) | 1.3 |
| (J) Net current financial indebtedness (I)-(E)-(D) | -26.8 |
| (K) Non-current bank loans | – |
| (L) Bonds issued | – |
| (M) Other current financial debt | 0.9 |
| (N) Non-current financial indebtedness (K)+(L)+(M) | 0.9 |
| (O) Net financial indebtedness (J)+(N) | -25.9 |
For further information, please contact:
Helén Tuvesson, CEO, +46 (0) 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 (0)46 19 20 44, hans.kolam@activebiotech.com
Active Biotech
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio
refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase I/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021. Please visit www.activebiotech.com for more information.
This is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 14.00 pm CET on January 5 2021.
IMPORTANT INFORMATION
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States unless registered under the US Securities Act of 1933, as amended (the “Securities Act”), or offered in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and in compliance with applicable United States state law. The offer and sale of the securities referred to herein have not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada and Japan. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Japan or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. In any EEA Member State other than Sweden, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of the Prospectus Regulation.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” within the meaning of the Prospectus Regulation who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, Relevant Persons. Persons who are not Relevant Persons should not take any action on the basis of this press release and should not act or rely on it.
This press release may contain forward-looking statements which reflect Active Biotech’s current view on future events and financial and operational development. Words such as “intend”, “will”, “expect”, “anticipate”, “may”, “plan”, “estimate” and other expressions that imply indications or predictions of future development or trends, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. The information, opinions and forward-looking statements included in this press release speak only as of its date and are subject to change without notice.
Attachment
